Dermatology Conference Coverage

Using a claims database, researchers found a steady increase in the prevalence of alopecia areata from 2016 to 2019 among those with employer-based health insurance. They also found a higher prevalence and incidence rate among women than among men.

Dupixent (dupilumab) ushered in a new era and a growing number of treatment options has brought awareness to the condition. But the panelists also discussed problems with step therapy, delays and denials of treatment and the lack of a “gold standard” test for diagnosis.